INTRODUCTION
Familial hypercholesterolemia (FH) was first described in 1920 (Burns, 1920) . It affects about one in 500 individuals (Graham et al., 2005) . FH is the most common single gene disorder and is mostly inherited as an autosomal dominant trait. The physical sign of FH is tendon xantomas, but these are not present in every family (Graham et al., 1999) . Identification and early treatment of affected individuals is desirable and in lack of physical symptoms DNA-based diagnosis provides confirmation of diagnosis and enables early patient management (Graham et al., 2005) . In the majority of FH cases individuals have defective low density lipoprotein receptor (LDLR) which leads to accumulation of low density lipoprotein cholesterol (LDL-C) in plasma (Graham et al., 2005; Humphries et al., 2006b) . Raised cholesterol concentrations in the blood are present from birth and lead to early development of atherosclerosis and coronary heart disease (DeMott, 2008) . About half of men with FH will develop coronary heart disease by the age of 55. FH-affected women typically develop coronary heart disease about nine years later than men (Slack, 1969) . The proportion of patients with FH identified and being treated is quite low, with most of these being young people (Humphries et al., 2006b) .
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Ilze Radovièa* # , Rûdolfs Bçrziòð*, Gustavs Latkovskis** , *** , ****, Dâvids Fridmanis*, Liene Òikitina-Zaíe*, Kârlis Ventiòð***, Guna Ozola**, Andrejs Çrglis** , *** , ****, and Jânis Kloviòð* * Latvian Biomedical Research and Study Centre, Râtsupîtes iela 1, Rîga, LV-1067, LATVIA; ilze@biomed.lu.lv, ruchka135@gmail.com, davids@biomed.lu.lv, lienik@biomed.lu.lv, klovins@biomed.lu (Graham et al., 2005) , especially by mutations in the LDLR-binding domain of APOB (Fisher et al., 1999) . This type of altered lipid level disease is called familial defective Apolipoprotein B (FDB). Various mutations in APOB gene are related to FDB and the most common one is Arg3527Gln (Chatzistefanidis et al., 2013) . Gain-offunction mutations in protein convertase subtilisin/kexin type 9 (PCSK9) have been proposed to cause increased degradation of LDLR, and the resulting reduction of LDLR receptor number on the cell surface could be a cause of yet another type of monogenic Hypercholesterolemia (Humphries et al., 2006b) . There is also evidence that functional mutations in low density lipoprotein adapter protein 1 (LDLRAP1) gene causing the recessive form of FH (Garcia et al., 2001) .
Several FH diagnosis criteria have been used, namely MedPed/WHO, Simon Broom and Dutch criteria, which may include TC and LDL-C levels, presence of tendon xanthomas or arcus cornealis in young individuals, family history and, in the latter case, presence of functional mutations (Anonymous, 1999; Defesche et al., 2004; Humphries et al., 2006a; ) . Recent findings, however, suggest higher prevalence of FH than previously thought and therefore the true prevalence of FH should be investigated as it may be underestimated by the current FH diagnostic criteria (Benn et al., 2012) . In this context, DNA-based evidence of functional mutations in LDLR, APOB and in PCSK9 genes is pivotal in making correct diagnosis (DeMott, 2008) .
There are several commercial genetic test kits available for identification of most common FH-causing mutations. However, the spectrum of disease-causing mutations is quite diverse in many populations (Graham et al., 2005) and for that reason commercially available kits may not be effective for diagnosis of the FH patient group in all populations. The Elucigen FH20 ARMS kit, for example, tests 20 mutations, which is only 44% of the FH-causative mutations in the United Kingdom (Taylor et al., 2010) . Therefore, determination of the most common mutations in LDLR, APOB, PCSK9, and LDLRAP1 in target populations might be required.
We conducted this pilot study to test whether the most common mutations used in commercially available tests occur in possible FH patients and patients with increased LDL-C in the Latvian population. In order to reach this goal our research was carried out in two stages. During the first stage we employed TaqMan probes to test seven relatively common mutations in the LDLR gene and one mutation in the APOB gene (Arg3527Gln). In the second stage we sequenced the coding regions of four FH-causing genes (LDLR, APOB, PCSK9, and LDLRAP1) employing AmpliSeq library preparation technology and the Ion Torrent Personal Genome Machine (PGM) Next Generation Sequencing (NGS) system.
MATERIALS AND METHODS

Subjects.
For this study we randomly selected 16 patients with elevated LDL-C (documented TC 7.0 mmol/L or higher and/or LDL-C 5.0 mmol/L or higher) from the Latvian Genome Database (LGDB), which on September of 2013 contained more than 22 000 DNA samples (~1% of the Latvian population) (Ignatovica et al., 2011) . In order to maintain consistency of clinical information, only patients recruited at the Latvian Centre of Cardiology were included in the study. Written informed consent was acquired from all LGDB participants. The study protocol was approved by the Central Medical Ethics Committee of Latvia (Protocols Nr. 2007 A-7, and 01-29.1/25).
Genotyping. For the purposes of our study we choose eight of the 20 most frequent functional mutations in LDLR and APOB genes. All chosen mutations are included in the commercially available Elucigen FH20 ARMS kit and listed in the SNP database of the National Centre for Biotechnology Information (dbSNP, build 138): (rs5742904, rs139624145, rs28942078, rs121908024, rs121908039, rs28942084, rs121908027 and rs121908028) (Taylor et al., 2010) . Prior to genotyping the concentration of DNA in the samples was normalised to 7 ng/µl. The concentration measurements were acquired using a spectrophotometer NANODROP ND-1000. Genotyping was carried out using an Applied Biosystems TaqMan SNP Genotyping Assay with a modified protocol described earlier . A total of eight mutations in 16 patients with FH were genotyped.
Next generation sequencing (NGS)
. In order to identify the overall functional mutation spectrum, all DNAs of the 16 patients were subjected to all exon sequencing of four FH-related genes. Sequencing was carried out at the Latvian Biomedical Research and Study Centre using Life Technologies Ion Torrent TM PGM equipment, which is based on semiconductor sequencing technology. ugi/fh) as well as other online sources of information were used to manually verify the previous annotations of all missense mutations and annotate missense mutations unannotated by automatic tools. PolyPhen-2 v2.2.2r398, an online tool for human SNP functional effect prediction, was employed to predict possible functional effects of detected mutations if no information was found in any of the previously mentioned sources.
Verification with Sanger sequencing. The verification of NGS-detected mutations was performed by Sanger Sequencing on an ABI Prism 3130XL Genetic Analyzer (Applied Biosystems) using region specific primer sequences that were designed for the AmpliSeq assay.
RESULTS
For the purposes of this research we selected 16 patients from LGDB with elevated LDL-C levels. According to the MedPed and WHO criteria, seven patients (43.8%) had probable FH, seven patients (43.8%) had possible FH and two patients (12.4%) would not be classified as having FH (World Health Organization, 1999) . 81.3% of all patients had hypertension and 87.5% had coronary heart disease. In total, all patients had either hypertension or coronary heart disease and 68.8% had both. 62.5% of all patients had history of myocardial infarction (mean age of 52), and 31.3% of all patients had known relatives with coronary heart disease. Most of the patients had history of revascularisation (percutaneous coronary intervention in 75% and coronary artery bypass grafting in 12.5% of cases, with one patient having history of both). Clinical characteristics of our cohort are summarised in Table 1. All selected patients were genotyped for the eight most frequent FH-causing mutations (Taylor et al., 2010) . Only one the patients was a carrier of the APOB gene (rs5742904) mutation in heterozygous state, thereby providing genetic confirmation of disease in 6.3% of cases.
We then performed NGS of all exons for four genes that are known to cause FH. Sequencing data analysis revealed that patients of the selected cohort were carriers of 29 missense mutations in total. One of these mutations (rs5742904) was already identified during RT-PCR analysis. We confirmed 21 mutations by Sanger sequencing. The remaining seven mutations were not confirmed with Sanger sequencing, and were either AmpliSeq PCR mistakes or aroused by mutation calling algorithms. All 22 verified missense mutations found in the 16 Latvian FH patients are summarised in Table 2.
Further data mining through various resources unveiled that nine of the mutations were already recorded in the HGMD Database (http://www.hgmd.org/), one was recorded in the Hypercholesterolemia (FH) Variant Database UCL (http://www.ucl.ac.uk/ldlr) and four were reported by various authors as associated with different lipid traits. Eight, however, had no reports of association with lipid metabolism alterations. One mutation rs5742904, located in the APOB gene, were reported to cause FH and was found in one patient (Soria et al., 1989; Taylor et al., 2010; Chatzistefanidis et al., 2013; ) . Another mutation (rs41291058) in LDLRAP1 gene had been linked to autosomal recessive FH (Garcia et al., 2001; Eden et al., 2002) . Four mutations (rs1367117, rs679899, rs533617 and rs562556), located in the APOB and PCSK9 genes, in the HGMD database were reported to be associated with altered lipid levels or altered binding efficiency (Shioji et al., 2004; Humphries et al., 2006b; Liao et al., 2008; Makela et al., 2012; Calandra et al., 2011; Al-Waili et al., 2013) . Another mutation (rs505151) in the PCSK9 gene was previously associated with atherosclerosis (Humphries et al., 2006b; Kotowski et al., 2006) . Two variants rs676210 from APOB and rs11591147 from PCSK9 were associated, respectively, with the protective BMI, kg/m 2 ± SD (min-max) 29.9 ± 5.5 (18.8-42.5) phenotype, hipocholesterolemia, and reduced risk for coronary heart disease (Cohen et al., 2004; Benn et al., 2010; Makela et al., 2012) . We also found a mutation in the PCSK9 gene (rs11583680) that was described in Familial Hypercholesterolemia (FH) Variant Databases UCL (http://www.ucl.ac.uk/ldlr) as a benign polymorphism (Fasano et al., 2007) . Three APOB gene variants found in our study group (rs1801701, rs1042031 and rs1801702) have been described by various authors as associated with different lipid traits and one as benign (rs1042034) (Liao et al., 2008; Makela et al., 2012; Calandra et al., 2011; Gaudreault et al., 2011) .
There was no information in the available resources regarding the association of eight missense mutations found in our data. The majority of these mutations were located in the APOB gene. In order to estimate the possible effect of the identified mutations on coded proteins we performed functional effect prediction using the online tool PolyPhen-2 v2.2.2r398 (http://genetics.bwh.harvard.edu/pph2/). This showed that one mutation (rs12713844) is possibly damaging and three mutations are possibly benign (rs1801696, rs568413 and rs11669576). Unfortunately, because of the lack of information PolyPhen-2 was not able to predict effects for the other mutations. (Makela et al., 2012) rs12713844
Altered binding affinity (Makela et al., 2012) rs72653092
33.8 Hypocholesterolaemia, association with (Makela et al., 2012) rs5742904 2 APOB Arg3527Gln C T 1 0 3,1 0.1 Hypercholesterolaemia (Soria et al., 1989; Taylor et al., 2010; Chatzistefanidis et al., 2013) rs1801701 2 APOB Arg3638Gln C T 3 0 9,4 4.9 (Calandra et al., 2011) rs1042031 2 APOB Glu4181Lys C T 6 0 18,8 15.3 (Liao et al., 2008; Calandra et al., 2011; Gaudreault et al., 2011; Makela et al., 2012) (Eden et al., 2002) rs11591147 1 PCSK9 Arg46Leu G T 1 0 3,1 0.9 Coronary heart disease, reduced risk, association with (Benn et al., 2010; Cohen et al., 2004) rs11583680 1 PCSK9 Ala53Val C T 2 1 12,5 9.0 (Fasano et al., 2007) rs562556 1 PCSK9 Ile474Val A G 7 1 28.1 14.7 High LDL cholesterol, association with (Al-Waili et al., 2013; Humphries et al., 2006b; Shioji et al., 2004) rs505151 1 PCSK9 Glu670Gly A G 2 1 12.5 9.8 Atherosclerosis, severity, association with (Humphries et al., 2006b; Kotowski et al., 2006) Chr -chromosome; AA substitution -amino acid substitution; Ref. allele -nucleotide of reference allele (Hg19); Alt allele -nucleotide of alternative allele.
DISCUSSION
In order to test the diagnostic efficiency of the commercially available UK population-based FH diagnosis panel for the Latvian population, we began this study by genotyping of 16 FH patients using TaqMan RT-PCR technology.
We tested for eight of the most frequent mutations of 20 that are used in the commercially available FH diagnosis panel. As a result we were able to gain genetic confirmation of FH diagnosis in only one case, where the heterozygous mutation in APOB gene (rs5742904) was detected. Thus, the employed mutation panel efficiency in the Latvian population was only 6.3%, which is too low to be considered a cost effective diagnostic tool. This result suggests that simplified employment of the panel for the most frequent mutations used for diagnosis of FH in the Latvian population is not as effective as in the UK, where 44% of FH cases can be confirmed. This also suggests that it is necessary to identify the most frequent FH causing mutations in the Latvian population, thus enabling the generation of a simple and inexpensive mutation panel for diagnosis of FH that is regionally efficient.
Since the efficiency of the genotyping was low, we performed sequencing of the coding regions of four FH related genes (LDLR, APOB, PCSK9, and LDLRAP1) using IonTorrent NGS technology. The goal of this analysis was to identify missense mutations that were missed by TaqMan probes. The data acquired from this analysis revealed that none of other most commonly tested mutations for diagnosis of FH in other countries (Taylor et al., 2010) were present. However, we found 21 other missense mutations, which are considered as less common. These results clearly show that mutation distributions differ between populations and that an alternative mutations panel could be used to confirm FH diagnosis in Latvian population. The majority of identified 22 missense mutations in most cases were located in the APOB gene. We found one mutation in the LDLRAP1 gene, which according to literature is associated with the autosomal recessive form of FH, but since this mutation was found in heterozygous state, direct genetic confirmation for FH diagnosis could not be established. However, it is possible that this mutation may cause FH in these patients, especially in combination with other mutations.
Our detailed sequence analysis identified four rare missense mutations that have been previously reported as associated with elevated lipid levels or also found in FH patients: rs533617, rs1801701, rs1801702 and rs505151. Similarly, one mutation (rs12713844) was determined by PolyPhen-2 as potentially damaging. Another four rare mutations (rs146152405, rs568413, rs151009667 and rs72653092) have no records of their linkage to FH. The majority of these mutations were found only in single individuals and thus can be considered as involved in the progression of disease. However, it is possible that at least some of them are benign in their nature, and further investigation of their functional effect and family based analysis is required. In total, eight patients (50.0%) from our study carry the above mentioned mutations (Table 3) .
Four more common variants (rs1357117, rs679899, rs1042031, and rs562556) have been associated with increased LDL-C or altered APOB levels (Shioji et al., 2004; Humphries et al., 2006b; Liao et al., 2008; Calandra et al., 2011; Gaudreault et al., 2011; Makela et al., 2012; Al-Waili et al., 2013) . There is no information available regarding their role in FH onset, but since there is an association with altered lipid levels and they have been detected in FH patients of various populations, it is possible that at least some of them can influence the progression of disease, especially in combination with rare mutations. In order to confirm this, however, research on the functional effects of these mutations should be carried out. In total, 14 patients (87.5%) from our study carry the above mentioned mutations (Table  3 ).
In conclusion, we detected only one out of eight very well-known FH causing mutations in our FH patient cohort. Further analysis based on targeted NGS was able to confirm FH diagnosis for one patient (6.3%). Mutations that possibly can alter LDL-C levels were found in eight patients. However, since our cohort is quite small, the estimated mutation frequencies cannot be extrapolated to the whole population, and further NGS-based investigation is needed to identify the most common FH-causing mutations in our population. Information of this kind would grant the opportunity to create a cost effective mutation detection panel for diagnosis of FH in the Latvian population. We also propose the NGS-based targeted sequencing panel as the most sensitive diagnostic tool available for the diagnosis of FH.
